Abstract
Sertindole is a novel antipsychotic agent with high selectivity for the mesolimbic dopaminergic pathway and nanomolar affinities for dopamine D2, serotonin 5-HT2, and norepinephrine NEα1 receptors. This 40-day randomized, placebo-controlled, dose-ranging multicenter study was designed to assess the effect of sertindole on previously neuroleptic-responsive, hospitalized schizophrenic patients (n=205). Sertindole doses began at 4 mg/day and were increased to 8, 12, or 20 mg/day, depending on randomization. Efficacy measures included the Positive and Negative Syndrome Scale (PANSS), Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression (CGI). Extrapyramidal symptoms (EPS) were assessed by movement rating scales, EPS-related adverse events, and use of anti-EPS medications. A dose-related improvement was observed for PANSS, BPRS, and CGI, with statistically significant mean differences (P<0.05) between placebo and 20-mg/day sertindole (decreases from baseline of −5.8 versus −16.9 for PANSS, −4.8 versus −10.4 for BPRS, respectively). The differences in CGI final improvement score between placebo and 20-mg/day sertindole were 3.8 versus 2.9, respectively. EPS-related events were comparable in the placebo and sertindole groups. In conclusion, sertindole 20 mg/day was effective, well tolerated, and not associated with significant motor system abnormalities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arnt J (1992) Sertindole and several antipsychotic drugs differentially inhibit the discriminative stimulus effects of amphetamine, LSD, and St 587 in rats. Behav Pharmacol 3:11–18
Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM (1992) Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 160 [suppl 17]12–16
Bunney BS (1984) Antipsychotic drug effects on the electrical activity of dopaminergic neurons. Trends Neurosci 7:212–215
Casey DE (1996) Behavioral effects of sertindole, risperidone, clozapine, and haloperidol inCebus monkeys. Psychopharmacology 124:134–140
COSTART (1989) Coding symbols for thesaurus of adverse reaction terms (3rd edn). Department of Health and Human Services. Food and Drug Administration, Center for Drugs and Biologics, Division of Drug and Biological Product Experience. Rockville, Md
Daniel D, Targum S, Zimbroff D, Mack R, Zborowski J, Morris D, Sebree T, Wallin B (1995) Efficacy, safety, and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients. Abstract, Meeting of the American College of Neuropsychopharmacology, Dec 10–15
Domeney AM, Arnt J, Costall B, Naylor RJ, Sánchez C, Smith AG (1994) Effect of sertindole on raised mesolimbic dopaminergic activity in the rat. Drug Dev Res 31:175–185
Goldstein JM (1995) Central and peripheral nervous systems: preclinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drugs 4:291–298
Grebb JA, Sebree T, Schmitz P, Kashkin K (1993) A placebo-controlled trial of sertindole in schizophrenia. Presented at the twenty-third annual meeting of the American College of Neuropsychopharmacology, Honolulu, Hawaii
Hyttel J (1991) Sertindole-a new concept in neuroleptic research. In: Modern trends in the treatment of schizophrenia: proceedings of a symposium. Excerpta Medica, Princeton, pp 3–12
Hyttel J, Neilsen JB, Nowak G (1992) The acute effect of sertindole on brain 5-HT2, D2 andαj receptors (ex vivo radioreceptor binding studies). J Neural Transm 89: 61–69
Malmberg A, Jackson DM, Eriksson A, Mohell N (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol 43:749–754
Meltzer HY, Nash FJ (1991) VII. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587–604
Meltzer HY, Gudelsky GA (1992) Dopaminergic and serotonergic effects of clozapine: implications for a unique clinical profile. Arzneimittelforschung 42:268
McEvoy J, Borison R, Small J, Van Kammen D, Melzer H, Hamner M, Morris D, Shu V, Sebree T, Grebb J, Kashkin K (1993) The efficacy and tolerability of sertindole in schizophrenic patients: a pilot, double-blind, placebo-controlled, dose-ranging study. Schizophr Res 9 [2, 3]:244
Sánchez C, Arnt J, Dragsted N, Hyttel J, Lembøl HL, Meier E, Perregaard J, Skarsfeldt T (1991) Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 22:239–250
SAS Institute, Inc (1991) SAS user's guide: statistics, version 6 edition. SAS Institute, Cary, NC
Skarsfeldt T (1992) Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 10:25–33
Trimble MR, Zarifian E (1985) Psychopharmacology of the limbic system. Br Assoc Psych, Monograph #5, Oxford University Press
Van Elteren PH (1960) On the combination of independent two sample tests of Wilcoxon. Bull Inst Int Statist 37:351–361
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Kammen, D.P., McEvoy, J.P., Targum, S.D. et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124, 168–175 (1996). https://doi.org/10.1007/BF02245618
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245618